BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gough A, Soto-Gutierrez A, Vernetti L, Ebrahimkhani MR, Stern AM, Taylor DL. Human biomimetic liver microphysiology systems in drug development and precision medicine. Nat Rev Gastroenterol Hepatol 2021;18:252-68. [PMID: 33335282 DOI: 10.1038/s41575-020-00386-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Nguyen OTP, Misun PM, Lohasz C, Lee J, Wang W, Schroeder T, Hierlemann A. An Immunocompetent Microphysiological System to Simultaneously Investigate Effects of Anti-Tumor Natural Killer Cells on Tumor and Cardiac Microtissues. Front Immunol 2021;12:781337. [PMID: 34925361 DOI: 10.3389/fimmu.2021.781337] [Reference Citation Analysis]
2 Kulsharova G, Kurmangaliyeva A. Liver microphysiological platforms for drug metabolism applications. Cell Prolif 2021;:e13099. [PMID: 34291515 DOI: 10.1111/cpr.13099] [Reference Citation Analysis]
3 Moreau M, Mallick P, Smeltz M, Haider S, Nicolas CI, Pendse SN, Leonard JA, Linakis MW, Mcmullen PD, Clewell RA, Clewell HJ, Yoon M. Considerations for Improving Metabolism Predictions for In Vitro to In Vivo Extrapolation. Front Toxicol 2022;4:894569. [DOI: 10.3389/ftox.2022.894569] [Reference Citation Analysis]
4 Hernandez-Jerez AF, Adriaanse P, Aldrich A, Berny P, Coja T, Duquesne S, Focks A, Marinovich M, Millet M, Pelkonen O, Pieper S, Tiktak A, Topping CJ, Widenfalk A, Wilks M, Wolterink G, Gundert-Remy U, Louisse J, Rudaz S, Testai E, Lostia A, Dorne JL, Parra Morte JM; EFSA Panel on Plant Protection Products and their Residues (EFSA PPR Panel). Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on testing and interpretation of comparative in vitro metabolism studies. EFSA J 2021;19:e06970. [PMID: 34987623 DOI: 10.2903/j.efsa.2021.6970] [Reference Citation Analysis]
5 Berridge BR. Animal Study Translation: The Other Reproducibility Challenge. ILAR Journal 2022. [DOI: 10.1093/ilar/ilac005] [Reference Citation Analysis]
6 Saydmohammed M, Jha A, Mahajan V, Gavlock D, Shun TY, DeBiasio R, Lefever D, Li X, Reese C, Kershaw EE, Yechoor V, Behari J, Soto-Gutierrez A, Vernetti L, Stern A, Gough A, Miedel MT, Lansing Taylor D. Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors. Exp Biol Med (Maywood) 2021;:15353702211009228. [PMID: 33957803 DOI: 10.1177/15353702211009228] [Reference Citation Analysis]
7 Kulsharova G, Kurmangaliyeva A, Darbayeva E, Rojas-Solórzano L, Toxeitova G. Development of a Hybrid Polymer-Based Microfluidic Platform for Culturing Hepatocytes towards Liver-on-a-Chip Applications. Polymers (Basel) 2021;13:3215. [PMID: 34641031 DOI: 10.3390/polym13193215] [Reference Citation Analysis]
8 Lee SY, Kim D, Lee SH, Sung JH. Microtechnology-based in vitro models: Mimicking liver function and pathophysiology. APL Bioeng 2021;5:041505. [PMID: 34703969 DOI: 10.1063/5.0061896] [Reference Citation Analysis]
9 Tricot T, Verfaillie CM, Kumar M. Current Status and Challenges of Human Induced Pluripotent Stem Cell-Derived Liver Models in Drug Discovery. Cells 2022;11:442. [DOI: 10.3390/cells11030442] [Reference Citation Analysis]
10 Liu Q, Shan Q. An optimization‐based stochastic model of the two‐compartment pharmacokinetics. Math Methods in App Sciences. [DOI: 10.1002/mma.8155] [Reference Citation Analysis]
11 Gerussi A, Natalini A, Antonangeli F, Mancuso C, Agostinetto E, Barisani D, Di Rosa F, Andrade R, Invernizzi P. Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. Int J Mol Sci 2021;22:4557. [PMID: 33925355 DOI: 10.3390/ijms22094557] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Wang J, Huang D, Yu H, Cheng Y, Ren H, Zhao Y. Developing tissue engineering strategies for liver regeneration. Engineered Regeneration 2022. [DOI: 10.1016/j.engreg.2022.02.003] [Reference Citation Analysis]
13 Nafshi R, Lezon TR. Predicting the Effects of Drug Combinations Using Probabilistic Matrix Factorization. Front Bioinform 2021;1:708815. [DOI: 10.3389/fbinf.2021.708815] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hasani N, Farhadi F, Morris MA, Nikpanah M, Rhamim A, Xu Y, Pariser A, Collins MT, Summers RM, Jones E, Siegel E, Saboury B. Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities. PET Clin 2022;17:13-29. [PMID: 34809862 DOI: 10.1016/j.cpet.2021.09.009] [Reference Citation Analysis]
15 Long Y, Niu Y, Liang K, Du Y. Mechanical communication in fibrosis progression. Trends Cell Biol 2022;32:70-90. [PMID: 34810063 DOI: 10.1016/j.tcb.2021.10.002] [Reference Citation Analysis]
16 Dong H, Li Z, Bian S, Song G, Song W, Zhang M, Xie H, Zheng S, Yang X, Li T, Song P. Culture of patient-derived multicellular clusters in suspended hydrogel capsules for pre-clinical personalized drug screening. Bioactive Materials 2022. [DOI: 10.1016/j.bioactmat.2022.03.020] [Reference Citation Analysis]